Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498103 | 0.96 | HDAC4 (0.44) | HSD11B1HDAC4SLC6A4SLC6A3HSD17B10 | |
| SCHEMBL10879701 | 0.94 | SLC6A4 (0.47) | HSD11B1HDAC4SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL695920 | 0.91 | HSD17B10 (0.41) | HSD11B1LIG1HDAC4SLC6A4SLC6A3 | |
| SCHEMBL27594932 | 0.82 | DRD2 (0.55) | HSD11B1HDAC4SLC6A4SLC6A3HSD17B10 | |
| Hydrochloric Acid SCHEMBL28029079 | 0.81 | DRD2 (0.53) | HDAC4SLC6A4SLC6A3HSD17B10DRD2 | |
| SCHEMBL13540015 | 0.80 | OPRM1 (0.51) | HSD11B1SLC6A4KCNH2 | |
| SCHEMBL12020399 | 0.79 | LIG1 (0.41) | HSD11B1LIG1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1335825 | 0.79 | ESR2 (0.48) | HSD11B1HSD17B10CYP3A4ALOX15 | |
| SCHEMBL20582009 | 0.79 | LIG1 (0.41) | LIG1 | |
| SCHEMBL22361954 | 0.79 | SLC6A4 (0.42) | HSD11B1LIG1HDAC4SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685363-A | ROR gamma t regulator, preparation method and application thereof | 上海医药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| EP-2321287-B1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-6339106-B1 | ADMINISTERING A RACEMIC OR OPTICALLY PURE SIBUTRANINE METABOLITE SUCH AS DESMETHYLSIBUTRAMINE, DIDESMETHYLSIBUTRAMINE OR ITS SALT OR SOLVATE OR CLATHRATE FOR THERAPY OF SEXUAL DYSFUNCTION | SEPRACOR, INC. | 2002-01-15 | — | — | US | disclosed |
| US-6331571-B1 | ADMINISTERING THERAPEUTICALLY OR PROPHYLACTICALLY EFFECTIVE AMOUNT OF RACEMIC OR OPTICALLY PURE SIBUTRAMINE METABOLITE, OR PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE, OR CLATHRATE THEREOF | SEPRACOR, INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001051453-A1 | RACEMIC AND OPTICALLY PURE METABOLITES OF SIBUTRAMINE, THEIR PREPARATION, COMPOSITIONS COMPRISING THEM AND THEIR USE AS DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1107746-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | Sepracor Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010551-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5430060-A | Aldose reductase inhibitor | ZENECA LIMITED (GB) | 1995-07-04 | — | — | US | disclosed |
| US-5047432-A | Antidepressants | THE BOOTS COMPANY PLC (GB) | 1991-09-10 | — | — | US | disclosed |
| US-4925879-A | ANTIDEPRESSANTS | BOOTS COMPANY, PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0191542-B1 | ARYLCYCLOBUTYLALKYL AMINES AND THEIR USE AS ANTIDEPRESSIVE MEDICINES | The Boots Company PLC (GB) | 1988-06-08 | — | — | EP | disclosed |
| EP-0191542-A1 | Arylcyclobutylalkyl amines and their use as antidepressive medicines | The Boots Company PLC (GB) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORC, RORB, RORA | HSD11B1 41/4885LIG1 4833/4885HDAC4 1168/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | HSD11B1 340/4885LIG1 779/4885HDAC4 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.